カテゴリ： GlobalData, アメリカ, 企業調査

Stemline Therapeutics Inc (STML)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Stemline Therapeutics Inc (STML) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C7600
◆発行会社（調査会社）：GlobalData
◆発行日：2018年10月
◆ページ数：62
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Stemline Therapeutics Inc (Stemline) is a clinical stage biopharmaceutical company that develops therapeutics to treat cancer stem cells and tumor bulk. The company has developed discovery platform StemScreen to identify novel compounds that target and kill cancer stem cells. Its products pipeline comprises of SL-401, SL-701, SL-801, SL-501 and SL-101. Stemline’s SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) present on CSCs and tumor bulk of hematologic cancers. The company’s SL-701 is an immunotherapy designed to activate the immune system to attack tumors. Its SL-801 is a novel oral small molecule reversible inhibitor of Exportin-1. Stemline is headquartered in New York, the US.

Stemline Therapeutics Inc (STML) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Stemline Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Stemline Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Stemline Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Stemline Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Stemline Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Stemline Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Stemline Therapeutics Raises US$0.74 Million In Venture Financing 11
Partnerships 12
Stemline Therapeutics Enters Into Co-Development Agreement With Leukemia & Lymphoma Society 12
Licensing Agreements 13
Stemline Therapeutics Enters into Licensing Agreement with UCB Biopharma 13
Stemline Therapeutics Enters into Licensing Agreement with CanBas 14
Stemline Therapeutics Enters into Licensing Agreement with CanBas for CBS-9106 15
Stemline Therapeutics Enters Into Licensing Agreement With University of Pittsburgh For EphA2 16
Stemline Therapeutics Enters Into Licensing Agreement With University of Pittsburgh For SL-701 17
Equity Offering 18
Stemline Therapeutics Plans to Raise up to USD50 Million in Public Offering of Shares 18
Stemline Therapeutics Raises USD59.6 Million in Public Offering of Shares 19
Stemline Therapeutics Prices Public Offering of Shares for USD45 Million 21
Stemline Therapeutics Raises USD60 Million in Public Offering of Shares 23
Stemline Therapeutics Announces Full Exercise Of Underwriter’s Option For Public Offering Of Shares For US$69 Million 25
Stemline Therapeutics Completes IPO For US$38.15 Million 27
Stemline Therapeutics Inc – Key Competitors 29
Stemline Therapeutics Inc – Key Employees 30
Stemline Therapeutics Inc – Locations And Subsidiaries 31
Head Office 31
Recent Developments 32
Financial Announcements 32
Aug 09, 2018: Stemline Therapeutics reports second quarter 2018 financial results 32
May 09, 2018: Stemline Therapeutics Reports First Quarter 2018 Financial Results 34
Mar 16, 2018: Stemline Therapeutics Announces Fourth Quarter 2017 Financial Results 35
Nov 09, 2017: Stemline Therapeutics Reports Third Quarter 2017 Financial Results 37
Aug 08, 2017: Stemline Therapeutics Reports Second Quarter 2017 Financial Results 38
May 10, 2017: Stemline Therapeutics Reports First Quarter 2017 Financial Results 39
Mar 16, 2017: Stemline Therapeutics Reports Fourth Quarter 2016 Financial Results 40
Corporate Communications 41
Apr 16, 2018: Stemline Therapeutics Expands Board of Directors; Further Enhances Commercial Expertise with Appointment of Darren Cline 41
Product News 42
12/13/2017: Stemline Therapeutics Presents Detailed SL-401 Pivotal Data in BPDCN at ASH and Kicks Off its BPDCN Awareness Campaign; Updated Results From Ongoing Trials in Additional Malignancies Also Presented 42
08/13/2018: Stemline Therapeutics announces that FDA accepts ELZONRIS Biologics License Application and grants Priority Review 44
06/18/2018: Stemline Therapeutics Announces Positive Clinical Data from ELZONRIS (tagraxofusp; SL-401) Trials in BPDCN, CMML and MF Delivered at the EHA Congress 45
Product Approvals 47
Jun 25, 2018: Stemline Therapeutics Announces Completion of Rolling BLA Submission for ELZONRIS (tagraxofusp; SL-401) for the Treatment of BPDCN 47
Apr 05, 2018: Stemline Therapeutics Announces Start of Rolling BLA Submission for SL-401 48
Clinical Trials 49
Jun 15, 2018: Stemline Therapeutics Announces Presentation of ELZONRIS (tagraxofusp; SL-401) Preclinical Data in Systemic Sclerosis, an Autoimmune Disorder, at EULAR Congress 49
Jun 14, 2018: Stemline Therapeutics Announces Three ELZONRIS (tagraxofusp; SL-401) Clinical Presentations, Including an Oral Presentation, at the EHA Congress 50
May 18, 2018: Stemline Therapeutics Announces Three SL-401 Clinical Presentations, Including an Oral Presentation, at the Upcoming EHA Congress 51
Dec 08, 2017: Stemline Therapeutics Announces Four SL-401 Presentations at Upcoming ASH Meeting 52
Nov 01, 2017: Stemline Announces Four SL-401 Presentations at Upcoming ASH Meeting 53
Oct 31, 2017: Stemline Therapeutics Announces that Pivotal Trial of SL-401 in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Meets Primary Endpoint 54
Jun 23, 2017: Stemline Therapeutics Presents SL-401 Updated Stage 1 and 2 Data from Ongoing Pivotal Trial in BPDCN and Safety Experience Across Multiple Indications, Today at EHA 55
May 18, 2017: Stemline Therapeutics to Present SL-401 Updated Data from Stage 1 and 2 of Ongoing Pivotal Phase 2 BPDCN Trial at Upcoming European Hematology Association Meeting 56
Mar 23, 2017: Stemline Therapeutics Announces Completion of Enrollment in Stage 3 of the SL-401 Pivotal Trial in BPDCN 57
Mar 16, 2017: Stemline Therapeutics Reports Fourth Quarter 2016 Financial Results 58
Feb 21, 2017: Stemline Therapeutics Provides Update on SL-401 59
Feb 02, 2017: Stemline Therapeutics Provides Update on Pivotal BPDCN Trial 60
Jan 05, 2017: Stemline Therapeutics Announces Positive FDA Meeting and Agreement on Expedited Pathway to Full Approval of SL-401 in First-Line BPDCN 61
Appendix 62
Methodology 62
About GlobalData 62
Contact Us 62
Disclaimer 62

List of Tables
Stemline Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Stemline Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Stemline Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Stemline Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Stemline Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Stemline Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Stemline Therapeutics Raises US$0.74 Million In Venture Financing 11
Stemline Therapeutics Enters Into Co-Development Agreement With Leukemia & Lymphoma Society 12
Stemline Therapeutics Enters into Licensing Agreement with UCB Biopharma 13
Stemline Therapeutics Enters into Licensing Agreement with CanBas 14
Stemline Therapeutics Enters into Licensing Agreement with CanBas for CBS-9106 15
Stemline Therapeutics Enters Into Licensing Agreement With University of Pittsburgh For EphA2 16
Stemline Therapeutics Enters Into Licensing Agreement With University of Pittsburgh For SL-701 17
Stemline Therapeutics Plans to Raise up to USD50 Million in Public Offering of Shares 18
Stemline Therapeutics Raises USD59.6 Million in Public Offering of Shares 19
Stemline Therapeutics Prices Public Offering of Shares for USD45 Million 21
Stemline Therapeutics Raises USD60 Million in Public Offering of Shares 23
Stemline Therapeutics Announces Full Exercise Of Underwriter's Option For Public Offering Of Shares For US$69 Million 25
Stemline Therapeutics Completes IPO For US$38.15 Million 27
Stemline Therapeutics Inc, Key Competitors 29
Stemline Therapeutics Inc, Key Employees 30

List of Figures
Stemline Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Stemline Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Stemline Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Stemline Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Stemline Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Stemline Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Stemline Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Stemline Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Stemline Therapeutics Inc (STML)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Lycamobile UK Limited：企業の戦略的SWOT分析
    Lycamobile UK Limited - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Laborie Medical Technologies Inc：企業の製品パイプライン分析2018
    Summary Laborie Medical Technologies Inc (Laborie), a subsidiary of Patricia Industries AB, develops and manufactures medical diagnostics and devices. The company offers uroflowmetry, urodynamics, pelvic floor rehabilitation and anorectal manometry products and related consumables. It also provides …
  • DiaSys Diagnostic Systems GmbH：医療機器：M&Aディール及び事業提携情報
    Summary DiaSys Diagnostic Systems GmbH (DiaSys Diagnostic) is a developer, manufacturer and marketer of point of care diagnostic products. The company’s products include automated analyzers, calibrators or controls, POCT systems and tests, reagents, system kits and OEM products. It provides automate …
  • Ames Construction Inc：企業の戦略的SWOT分析
    Ames Construction Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Oil States International, Inc. (OIS)-石油・ガス分野：企業M&A・提携分析
    Summary Oil States International, Inc. (Oil States) is an oilfield services company. It offers specialty products and services to oil and natural gas companies. The company’s product portfolio includes subsea equipment and offshore vessel, rig equipment, flexible bearings, connection systems, subsea …
  • Jamaica Public Service Co Ltd：企業の戦略的SWOT分析
    Jamaica Public Service Co Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produ …
  • Triumph Group Inc：企業のM&A・事業提携・投資動向
    Triumph Group Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Triumph Group Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), div …
  • Centrica Plc (CNA)-エネルギー分野：企業M&A・提携分析
    Summary Centrica plc (Centrica) is an integrated energy company. It carries out electricity generation through and combined cycle gas turbine (CCGT) power stations, and nuclear power plants through its stake in EDF Energy Nuclear Generation. Centrica secures and supply gas and electricity to homes a …
  • Shenzhen Jinjia Group Co., Ltd.：企業の戦略・SWOT・財務情報
    Shenzhen Jinjia Group Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Shenzhen Jinjia Group Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Localiza Rent A Car SA：企業の戦略・SWOT・財務情報
    Localiza Rent A Car SA - Strategy, SWOT and Corporate Finance Report Summary Localiza Rent A Car SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • University Hospitals-製薬・医療分野：企業M&A・提携分析
    Summary University Hospitals is a healthcare service provider that offers patient-centered medical care and education services. The center includes network of specialty care physicians, skilled nursing, elder health, rehabilitation and home care services, managed care and insurance programs, occupat …
  • Australian Pharmaceutical Industries Ltd (API)：企業の財務・戦略的SWOT分析
    Australian Pharmaceutical Industries Ltd (API) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key str …
  • Siccar Point Energy Ltd：石油・ガス：M&Aディール及び事業提携情報
    Summary Siccar Point Energy Ltd (Siccar Point) is an oil and gas company that offers exploration and development of energy fields. The company acquires, and targets both operated and non-operated opportunities. Its exploration areas include Schiehallion field, Rosebank field, Suilven field, Cambo fi …
  • Kajima Corporation：企業の戦略・SWOT・財務情報
    Kajima Corporation - Strategy, SWOT and Corporate Finance Report Summary Kajima Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Baloise Holding Ltd：企業の戦略・SWOT・財務情報
    Baloise Holding Ltd - Strategy, SWOT and Corporate Finance Report Summary Baloise Holding Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Kura Oncology Inc (KURA)：企業の財務・戦略的SWOT分析
    Summary Kura Oncology Inc (Kura Oncology) is a clinical-stage biopharmaceutical company that discovers and develops therapeutics for the treatment of solid tumors and blood cancers. The company’s lead drug candidate Tipifarnib, an inhibitor of farnesyl transferase, an oral investigational drug candi …
  • Pirelli & C. S.p.A.：戦略・SWOT・企業財務分析
    Pirelli & C. S.p.A. - Strategy, SWOT and Corporate Finance Report Summary Pirelli & C. S.p.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Awilco LNG ASA (ALNG)：石油・ガス：M&Aディール及び事業提携情報
    Summary Awilco LNG ASA (Awilco LNG), a subsidiary of Awilhelmsen AS, is an oil and gas company that provides LNG transportation programs. The company owns and operates LNG vessels intended for international trading. It offers LNG value chain such as liquefaction, production, regasification, transpor …
  • Morgans Hotel Group Co：戦略・SWOT・企業財務分析
    Morgans Hotel Group Co - Strategy, SWOT and Corporate Finance Report Summary Morgans Hotel Group Co - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Quadra – Power Generation：企業の発電所・SWOT分析2018
    Quadra - Power Generation - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key emp …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆